Mankind Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+17.0%+18.1%+18.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+19.9%+19.0%+33.4%
+14.0%+12.2%+35.7%
−3.6%+3.6%+48.3%
−5.9%+3.2%+49.2%
+1.2%+132.0%+23.1%
+13.7%+52.1%+25.6%
+29.3%+12.1%+18.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MANKIND₹2,469.30

Mankind Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLATORNTPHARMLAURUSLABSBIOCONALKEMLUPINGLENMARKMcap ₹1.02L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+18.1+18.1+17.0—
EBITDA Growth—+33.4+19.0+19.9—
EBIT Growth—+35.7+12.2+14.0—
Net Income Growth—+48.3+3.6-3.6—
EPS Growth—+49.2+3.2-5.9—
Total Assets Growth—+23.1+132.0+1.2—
Total Equity Growth—+25.6+52.1+13.7—
Cash from Operations Growth—+18.7+12.1+29.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.